JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder
Head-to-head, Phase 3 study of weekly and monthly buprenorphine depots (CAM2038) vs standard treatment with daily sublingual buprenorphine/naloxone. CAM2038 met the primary endpoint of non-inferiority and demonstrated superiority for the first secondary endpoint. Lund — 14 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today the publication in the Journal of the American Medical Association (JAMA) Internal Medicine of positive Phase 3 pivotal study results for the company’s weekly and monthly subcutaneous (SC) buprenorphine depots (CAM2038), supporting efficacy and potential